BIO.COM: Biotechnology Pharmaceutical Therapeutics,... -
[Cached Version]
Published on: 11/19/2004
Last Visited: 1/7/2006
In this study, Dr. Wittschieben--working in the laboratory of Richard D. Wood, Ph.D., professor of pharmacology, the Richard M. Cyert Chair in Molecular Oncology and director of the molecular and cellular oncology program at the University of Pittsburgh Cancer Institute--sought to determine pol zeta's key role in mice cells.
...
To do this, Drs. Wittschieben and Wood disabled, or "knocked out," the gene for pol zeta's Rev3L subunit, the part with the lesion-replicating capabilities.
...
According to Dr. Wood, these findings have significant implications for human cancer research, in that such a high degree of chromosomal instability is a characteristic of cancer cells.Furthermore, the human Rev3L gene is located in a segment of chromosome 6 where multiple tumor suppressor genes are believed to reside and a slew of human cancers, including a number of leukemias and lymphomas, are associated with chromosomal instabilities in this particular region of chromosome 6.
"Although it requires further investigation, we believe that mutations in this part of chromosome 6 could occur during the development of some cancers and this may have prognostic and therapeutic implications.We are now investigating this hypothesis by selectively deleting the Rev3L gene in adult mouse cells to study how the loss of DNA polymerase zeta influences the development and progression of spontaneous cancers," explained Dr. Wood.